Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin

BMC Research Notes

Mototsugu Oya¹  Akira Miyajima¹  Shuji Mikami¹  Eiji Kikuchi¹  Hiroki Ide¹ 

[1] Department of Urology and Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

关键词: Thymidylate synthase;    Dihydropyrimidine dehydrogenase;    5-fluorouracil;    S-1;    Urothelial carcinoma;   

Others  :  1129494
DOI  :  10.1186/1756-0500-7-646

 received in 2014-07-23, accepted in 2014-09-11,  发布年份 2014

【 摘 要 】

Background

Recently, it has been shown that 5-fluorouracil (5-FU) with a strong dihydropyrimidine dehydrogenase (DPD) inhibitor elicits a significant response in bladder cancer with a high level of DPD. However, only a few studies investigated the association between the level of the enzyme that regulates the metabolism of 5-FU and prognosis in bladder cancer. Furthermore, to our knowledge, there has also been no such report in T1G3 bladder tumors treated with BCG. Therefore, we evaluated enzymes that regulate the metabolism of 5-FU in T1G3 tumors treated with BCG immunotherapy using the Danenberg tumor profile (DTP) method, a highly accurate measurement of RNA from paraffin-embedded specimens.

Methods

This study included 28 patients with T1G3 bladder cancer, each of whom underwent complete transurethral tumor resection and BCG intravesical instillation at our institution. The median follow-up period was 39 months (range, 3 to 159 months). The DTP method was used to analyze the mRNA expression of 3 enzymes related to 5-FU: DPD, orotate phosphoribosyltransferase (OPRT), and thymidylate synthase (TS).

Results

Among the 28 patients, 13 developed recurrences (46.4%) and 5 experienced disease progression (17.9%). An elevated DPD mRNA level was significantly associated with recurrence (p = 0.048) and progression (p = 0.045). However, TS and OPRT mRNA levels were not significantly associated with any other clinical features or outcomes. Furthermore, the high DPD group had a significantly lower recurrence-free survival rate than the low DPD group (p = 0.047). Among patients with low DPD, the 2- and 5-year recurrence-free survival rates were 88.9% and 74.1%, respectively; while among patients with high DPD, the corresponding rates were 61.3% and 36.8%, respectively. TS and OPRT were not significantly associated with recurrence-free survival rates.

Conclusion

DPD is significantly associated with recurrence and progression among T1G3 bladder cancer patients treated with BCG.

【 授权许可】

   
2014 Ide et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N, Miki T: Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 2001, 92(3):510-518.
• [2]Mizutani Y, Wada H, Fukushima M, Yoshida O, Ukimura O, Kawauchi A, Miki T: The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur J Cancer 2001, 37(5):569-575.
• [3]Mizutani Y, Wada H, Fukushima M, Yoshida O, Nakanishi H, Li YN, Miki T: Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer 2004, 100(4):723-731.
• [4]Mizutani Y, Wada H, Yoshida O, Fukushima M, Bonavida B, Kawauchi A, Miki T: Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer. Oncol Rep 2002, 9(2):289-292.
• [5]Kubota Y, Hosaka M, Fukushima S, Kondo I: Prophylactic oral UFT therapy for superficial bladder cancer. Cancer 1993, 71(5):1842-1845.
• [6]Ide H, Kikuchi E, Hasegawa M, Kozakai N, Kosaka T, Miyajima A, Oya M: Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma. BMC Cancer 2012, 12:420. BioMed Central Full Text
• [7]Sanchez-Carbayo M, Cordon-Cardo C: Molecular alterations associated with bladder cancer progression. Semin Oncol 2007, 34(2):75-84.
• [8]Azuma H, Inamoto T, Takahara K, Ibuki N, Nomi H, Yamamoto K, Narumi Y, Ubai T: Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: development of novel bladder preservation approach, Osaka Medical College regimen. Int J Urol 2012, 19(1):26-38.
• [9]Koga F, Kihara K: Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. Int J Urol 2012, 19(5):388-401.
• [10]Simone G, Papalia R, Ferriero M, Guaglianone S, Castelli E, Collura D, Muto G, Gallucci M: Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol 2013, 20(4):390-397.
• [11]Lamm DL: Preventing progression and improving survival with BCG maintenance. Eur Urol 2000, 37(Suppl 1):9-15.
• [12]Patard JJ, Rodriguez A, Leray E, Rioux-Leclercq N, Guille F, Lobel B: Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 2002, 41(6):635-641. discussion 642
• [13]Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE: Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 2004, 172(1):70-75.
• [14]Horikoshi T, Danenberg K, Volkenandt M, Stadlbauer T, Danenberg PV: Quantitative measurement of relative gene expression in human tumors. Methods Mol Biol 1993, 15:177-188.
• [15]Ichikawa W, Takahashi T, Suto K, Nihei Z, Shirota Y, Shimizu M, Sasaki Y, Hirayama R: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 2004, 112(6):967-973.
• [16]Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA: Laser capture microdissection. Science 1996, 274(5289):998-1001.
• [17]Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998, 22(12):1435-1448.
• [18]Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, Liotta LA: Laser capture microdissection: molecular analysis of tissue. Science 1997, 278(5342):1481,1483.
• [19]Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI, Danenberg PV: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000, 4(2):135-142.
• [20]Atzpodien J, Royston P, Wandert T, Reitz M: Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003, 88(3):348-353.
• [21]Lebret T, Becette V, Barbagelatta M, Herve JM, Gaudez F, Barre P, Lugagne PM, Botto H: Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol 1998, 159(3):788-791.
• [22]Alvarez-Mugica M, Cebrian V, Fernandez-Gomez JM, Fresno F, Escaf S, Sanchez-Carbayo M: Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. J Urol 2010, 184(4):1507-1513.
• [23]Li Y, Li X, Dai H, Sun X, Li J, Yang F, Gu H, Yang Y, Jin Z, Chu Y, Jin X, Kakehi Y, Wu X: Thymidylate synthase was associated with patient prognosis and the response to adjuvant therapy in bladder cancer. BJU Int 2009, 103(4):547-552.